The company’s senior leadership announced the transition of CFO Michael J. Tokich, a veteran of 17 years with the firm, to Senior Financial Advisor, a new role that will allow him to continue contributing to the company’s growth and success. The role of CFO will be taken over by Karen L. Burton, who has been with the company for 20 years and currently serves as Chief Accounting Officer (CAO).
Background and Experience
Michael J. Tokich has been with STERIS since 2000, serving in various roles including Assistant Controller and Senior Vice President and CFO. During his tenure, Tokich has played a significant role in shaping the company’s financial strategy and has been instrumental in driving growth and success. Tokich’s experience and leadership skills have been recognized and appreciated by the company’s leadership, with Dan Carestio, President and CEO, stating that “Mike’s contributions over the past 25 years at STERIS have been instrumental in our growth and success.”
Karen L. Burton has been with STERIS since 2004, starting as Assistant Controller and rising through the ranks to become CAO in 2017. She has extensive experience in finance and accounting, and has played a key role in the company’s financial strategy and operations. Burton has worked closely with Tokich for many years, and the two will ensure a smooth transition of the CFO role.
Transition and Leadership
The transition of Tokich to Senior Financial Advisor will take place on August 18, 2025, and Burton will assume the role of CFO, reporting to Carestio. The two have worked together for many years and have a deep understanding of the company’s financial operations and strategy. The transition is seen as a well-planned succession, with Carestio stating that “This has been a well-planned succession, which is a credit to both Karen and Mike. I am confident it will be a smooth transition.”
STERIS’s Commitment to Innovation and Growth
STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention. The company is committed to innovation and growth, and has made significant investments in new technologies and initiatives. The leadership team is confident that the transition of Tokich to Senior Financial Advisor and Burton to CFO will not impact the company’s ability to drive growth and success.
- STERIS’s commitment to innovation and growth is reflected in its investments in new technologies and initiatives.
- The company’s focus on infection prevention has enabled it to provide high-quality products and services to its customers.
- STERIS’s leadership team is confident in its ability to drive growth and success, despite the transition of key personnel.
About STERIS
STERIS is a global provider of products and services that support patient care. The company is committed to providing high-quality products and services that meet the needs of its customers. STERIS is a leader in the infection prevention industry, and its products and services are used in hospitals and healthcare facilities around the world.
| Company Overview | Products and Services | Global Presence |
|---|---|---|
| STERIS is a leading global provider of products and services that support patient care. | The company provides a range of products and services, including infection prevention products and services. | STERIS has a global presence, with operations in over 100 countries. |
Company Contact
For more information, please contact:
* Julie Winter, Vice President, Investor Relations and Corporate Communications
* Julie_Winter@steris.com
* +1.440.392.7245
“STERIS is a leader in the infection prevention industry, and its products and services are used in hospitals and healthcare facilities around the world. We are committed to providing high-quality products and services that meet the needs of our customers.” – Dan Carestio, President and CEO
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION
This release and the referenced conference call may contain statements concerning certain trends, expectations, forecasts, estimates, or other forward-looking information affecting or relating to STERIS or its industry, products or activities that are intended to qualify for the protections afforded “forward-looking statements” under the Private Securities Litigation Reform Act of 1995 and other laws and regulations. Forward-looking statements speak only as to the date the statement is made and may be identified by the use of forward-looking terms such as “may,” “will,” “expects,” “believes,” “anticipates,” “plans,” “estimates,” “projects,” “targets,” “forecasts,” “outlook,” “impact,” “potential,” “confidence,” “improve,” “optimistic,” “deliver,” “orders,” “backlog,” “comfortable,” “trend,” and “seeks,” or the negative of such terms or other variations on such terms or comparable terminology.